Condition: Acute Ischemic Stroke · Sponsor: The Florey Institute of Neuroscience and Mental Health
STARS is a prospective, multicentre, open-label, dose escalation, Phase IIa study to assess the safety and tolerability of TBO-309, an adjuvant antiplatelet therapy, in patients with AIS. Acute ischaemic stroke (AIS) is caused by a severe blockage of an artery leading to immediate reduced blood flow to part of the brain. Standard therapies target the blocked artery by either dissolving the blockage or removing the blockage. However, even after successful treatment, re-blockage of arteries can occur. The use of an antiplatelet therapy, TBO-309, in addition to standard therapies offers the possibility of improved restoration of blood flow and reduced rates of artery re-blockage.
This description comes directly from the study's public registry record.
Candice Delcourt, Dr · +61 2 8052 4601 · cdelcourt@georgeinstitute.org.au
Michele Sallaberger · +61 438471423 · michele.sallaberger@florey.edu.au
Always discuss trial participation with your own doctor first.
| Royal Prince Alfred Hospital | Camperdown, New South Wales, Australia | Recruiting |
| Liverpool Hospital | Liverpool, New South Wales, Australia | Recruiting |
| John Hunter Hospital | New Lambton Heights, New South Wales, Australia | Recruiting |
| Prince of Wales Hospital | Randwick, New South Wales, Australia | Recruiting |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | Recruiting |
| Eastern Health- Box Hill Hospital | Box Hill, Victoria, Australia | Recruiting |
| Royal Melbourne Hospital | Parkville, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05363397